- Home
- NXC vs INCR Comparison
NXC vs INCR Comparison
Compare NXC & INCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXC
- INCR
- Stock Information
- Founded
- NXC 1992
- INCR 1994
- Country
- NXC United States
- INCR Israel
- Employees
- NXC N/A
- INCR N/A
- Industry
- NXC Investment Managers
- INCR Biotechnology: Pharmaceutical Preparations
- Sector
- NXC Finance
- INCR Health Care
- Exchange
- NXC Nasdaq
- INCR Nasdaq
- Market Cap
- NXC 87.3M
- INCR 80.1M
- IPO Year
- NXC N/A
- INCR N/A
- Fundamental
- Price
- NXC $13.34
- INCR $1.32
- Analyst Decision
- NXC
- INCR
- Analyst Count
- NXC 0
- INCR 0
- Target Price
- NXC N/A
- INCR N/A
- AVG Volume (30 Days)
- NXC 17.5K
- INCR 54.3K
- Earning Date
- NXC 01-01-0001
- INCR 12-03-2024
- Dividend Yield
- NXC 3.97%
- INCR N/A
- EPS Growth
- NXC N/A
- INCR N/A
- EPS
- NXC 0.19
- INCR N/A
- Revenue
- NXC N/A
- INCR $72,420,918.00
- Revenue This Year
- NXC N/A
- INCR N/A
- Revenue Next Year
- NXC N/A
- INCR $39.30
- P/E Ratio
- NXC $70.47
- INCR N/A
- Revenue Growth
- NXC N/A
- INCR N/A
- 52 Week Low
- NXC $11.86
- INCR $1.12
- 52 Week High
- NXC $13.70
- INCR $3.72
- Technical
- Relative Strength Index (RSI)
- NXC 35.16
- INCR 35.86
- Support Level
- NXC $13.40
- INCR $1.17
- Resistance Level
- NXC $13.80
- INCR $1.54
- Average True Range (ATR)
- NXC 0.12
- INCR 0.10
- MACD
- NXC -0.02
- INCR -0.01
- Stochastic Oscillator
- NXC 11.54
- INCR 24.59
About NXC Nuveen California Select Tax-Free Income Portfolio
Nuveen CA Select Tax Free Income Port is a diversified closed-end management investment company. Its objective is to provide stable dividends exempt from both regular federal and California income taxes, consistent with the preservation of capital by investing primarily in municipal obligations.
About INCR Intercure Ltd.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.